JP6405319B2 - 乳癌予知のための画像分析 - Google Patents

乳癌予知のための画像分析 Download PDF

Info

Publication number
JP6405319B2
JP6405319B2 JP2015550033A JP2015550033A JP6405319B2 JP 6405319 B2 JP6405319 B2 JP 6405319B2 JP 2015550033 A JP2015550033 A JP 2015550033A JP 2015550033 A JP2015550033 A JP 2015550033A JP 6405319 B2 JP6405319 B2 JP 6405319B2
Authority
JP
Japan
Prior art keywords
score
heterogeneity
her2
breast cancer
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015550033A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503167A (ja
JP2016503167A5 (enExample
Inventor
チュッカ，シュリニヴァス
サルカル，アニンディヤ
シェンプ，クリスタル
セルテル，オルケイ
スィン，シャリニ
タブス，レイモンド
ワリング，ポール・マイケル
ヴィック，ニコラウス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of JP2016503167A publication Critical patent/JP2016503167A/ja
Publication of JP2016503167A5 publication Critical patent/JP2016503167A5/ja
Application granted granted Critical
Publication of JP6405319B2 publication Critical patent/JP6405319B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H30/00—ICT specially adapted for the handling or processing of medical images
    • G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
JP2015550033A 2012-12-28 2013-12-19 乳癌予知のための画像分析 Active JP6405319B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261747148P 2012-12-28 2012-12-28
US61/747,148 2012-12-28
PCT/EP2013/077295 WO2014102130A1 (en) 2012-12-28 2013-12-19 Image analysis for breast cancer prognosis

Publications (3)

Publication Number Publication Date
JP2016503167A JP2016503167A (ja) 2016-02-01
JP2016503167A5 JP2016503167A5 (enExample) 2016-12-28
JP6405319B2 true JP6405319B2 (ja) 2018-10-17

Family

ID=49917058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015550033A Active JP6405319B2 (ja) 2012-12-28 2013-12-19 乳癌予知のための画像分析

Country Status (8)

Country Link
US (2) US11211167B2 (enExample)
EP (1) EP2939026B1 (enExample)
JP (1) JP6405319B2 (enExample)
AU (1) AU2013369439B2 (enExample)
CA (1) CA2890964C (enExample)
DK (1) DK2939026T3 (enExample)
ES (1) ES2639559T3 (enExample)
WO (1) WO2014102130A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105008919B (zh) * 2013-03-06 2018-11-13 生物研究技术公司 分子成像和相关方法
EP3155592B1 (en) * 2014-06-10 2019-09-11 Leland Stanford Junior University Predicting breast cancer recurrence directly from image features computed from digitized immunohistopathology tissue slides
EP3227833B1 (en) * 2014-12-03 2024-12-25 Ventana Medical Systems, Inc. Systems and methods for early-stage cancer prognosis
US9953133B2 (en) 2015-06-03 2018-04-24 General Electric Company Biological data annotation and visualization
US10672505B2 (en) 2015-06-03 2020-06-02 General Electric Company Biological data annotation and visualization
US9613254B1 (en) 2015-09-30 2017-04-04 General Electric Company Quantitative in situ characterization of heterogeneity in biological samples
US20170234874A1 (en) * 2015-10-07 2017-08-17 Clearbridge Biophotonics Pte Ltd. Integrated visual morphology and cell protein expression using resonance-light scattering
WO2018118786A1 (en) * 2016-12-19 2018-06-28 Ventana Medical Systems, Inc. Methods and systems for quantitative immunohistochemistry
JP7278224B2 (ja) * 2017-06-02 2023-05-19 コーニンクレッカ フィリップス エヌ ヴェ 医用画像の病変の定量化される態様
CN107271671A (zh) * 2017-06-05 2017-10-20 龚畅 一种预测er（+）乳腺癌新辅助化疗效果的试剂盒和系统
US10586376B2 (en) * 2017-06-13 2020-03-10 Optrascan, Inc. Automated method of predicting efficacy of immunotherapy approaches
RU2664671C1 (ru) * 2017-07-28 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ прогноза рака молочной железы
CN111448584B (zh) * 2017-12-05 2023-09-26 文塔纳医疗系统公司 计算肿瘤空间和标记间异质性的方法
JP7197584B2 (ja) * 2017-12-06 2022-12-27 ベンタナ メディカル システムズ， インコーポレイテッド デジタル病理学分析結果の格納および読み出し方法
US11568657B2 (en) 2017-12-06 2023-01-31 Ventana Medical Systems, Inc. Method of storing and retrieving digital pathology analysis results
EP3721373B1 (en) 2017-12-07 2025-03-05 Ventana Medical Systems, Inc. Deep-learning systems and methods for joint cell and region classification in biological images
EP3729369A2 (en) 2017-12-24 2020-10-28 Ventana Medical Systems, Inc. Computational pathology approach for retrospective analysis of tissue-based companion diagnostic driven clinical trial studies
US11621058B2 (en) 2018-02-08 2023-04-04 Ohio State Innovation Foundation Synthetic IHC-stained digital sides generated using artificial neural networks
WO2019197509A1 (en) 2018-04-13 2019-10-17 Ventana Medical Systems, Inc. Systems for cell shape estimation
US12020493B2 (en) 2018-07-27 2024-06-25 Ventana Medical Systems, Inc. Systems for automated in situ hybridization analysis
WO2020046773A1 (en) 2018-08-31 2020-03-05 Ventana Medical Systems, Inc. Contextually adaptive digital pathology interface
WO2020056338A1 (en) * 2018-09-14 2020-03-19 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
JP7228031B2 (ja) 2018-10-15 2023-02-22 ベンタナ メディカル システムズ， インコーポレイテッド 細胞の分類のためのシステムおよび方法
CN113226157B (zh) * 2018-12-19 2025-03-18 匹兹堡大学高等教育联邦体系 用于原位或体外多参数细胞和亚细胞成像数据的计算系统病理学空间分析平台
JP7227389B2 (ja) 2019-02-13 2023-02-21 ベンタナ メディカル システムズ， インコーポレイテッド マルチチャネル画像における自己蛍光の寄与を算出するシステムおよび方法
JP7593112B2 (ja) * 2019-02-15 2024-12-03 コニカミノルタ株式会社 情報提供方法、情報提供装置及びプログラム
US11726757B2 (en) * 2019-08-14 2023-08-15 Nvidia Corporation Processor for performing dynamic programming according to an instruction, and a method for configuring a processor for dynamic programming via an instruction
EP4022286A1 (en) 2019-08-28 2022-07-06 Ventana Medical Systems, Inc. Label-free assessment of biomarker expression with vibrational spectroscopy
KR20220064379A (ko) 2019-09-09 2022-05-18 페이지.에이아이, 인크. 바이오마커들을 추론하기 위해 슬라이드의 이미지들을 처리하기 위한 시스템들 및 방법들
CN110853022B (zh) * 2019-11-14 2020-11-06 腾讯科技（深圳）有限公司 病理切片图像的处理方法、装置、系统及存储介质
WO2021146705A1 (en) 2020-01-19 2021-07-22 Ventana Medical Systems, Inc. Non-tumor segmentation to support tumor detection and analysis
CN115088022A (zh) 2020-02-11 2022-09-20 文塔纳医疗系统公司 用于训练机器学习算法和维护患者隐私的联邦学习系统
US20210287801A1 (en) * 2020-03-11 2021-09-16 Biosyntagma, Inc. Method for predicting disease state, therapeutic response, and outcomes by spatial biomarkers
CN115552534A (zh) * 2020-03-18 2022-12-30 赛诺菲 用于预测表达水平的系统和方法
CN115997241A (zh) * 2020-08-13 2023-04-21 佩治人工智能公司 处理电子图像进行连续生物标志物预测的系统和方法
DE102020211271A1 (de) * 2020-09-08 2022-03-10 Siemens Healthcare Gmbh Erzeugung eines Biomarkers quantifizierend eine räumliche Homogenität einer medizinischen Parameterkarte
EP4217393A1 (en) * 2020-09-22 2023-08-02 Ventana Medical Systems, Inc. Prediction of response to epidermal growth factor receptor-directed therapies using epiregulin and amphiregulin
CN112801939B (zh) * 2020-12-31 2022-07-22 杭州迪英加科技有限公司 一种用于提高病理图像ki67指标准确性的方法
US20240295561A1 (en) * 2021-06-17 2024-09-05 Konica Minolta, Inc. Quantification method and labeling method
CN113970638B (zh) * 2021-10-24 2023-02-03 清华大学 确定胃癌极早期发生风险及评估胃癌前病变进展风险的分子标志及其在诊断试剂盒中的应用
CN119654686A (zh) * 2022-08-08 2025-03-18 文塔纳医疗系统公司 用于对数字化病理学载玻片的定量的系统和方法
WO2024178422A1 (en) * 2023-02-24 2024-08-29 Ohio State Innovation Foundation Novel image-based metrics of her2 heterogeneity
WO2024259271A2 (en) * 2023-06-15 2024-12-19 New York University Systems, methods and computer-accessible medium for determining and/or analysing cancer outcome(s) and/or treatment responses
WO2025014787A1 (en) * 2023-07-07 2025-01-16 Ventana Medical Systems, Inc. Brightfield triplex immunohistochemistry assay for evaluating the colocalization of the er, pr, and ki-67 biomarkers in cells
WO2025106811A1 (en) * 2023-11-15 2025-05-22 4D Path Inc. Systems and methods for image-based disease characterization
KR20250156974A (ko) 2024-04-26 2025-11-04 사회복지법인 삼성생명공익재단 딥러닝 모델을 이용한 종양 미세환경 예측 방법 및 분석장치

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444487A (en) 1979-07-02 1984-04-24 Xerox Corporation Multiple-flash fuser
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
EP0256654B1 (en) 1986-07-07 1996-09-18 Centocor, Inc. Chimeric murine/human immunoglobulin specific for tumour-associated 17-1A Antigen
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
GB0229734D0 (en) 2002-12-23 2003-01-29 Qinetiq Ltd Grading oestrogen and progesterone receptors expression
US20050136549A1 (en) * 2003-10-30 2005-06-23 Bioimagene, Inc. Method and system for automatically determining diagnostic saliency of digital images
US8787651B2 (en) * 2010-09-28 2014-07-22 Flagship Biosciences, LLC Methods for feature analysis on consecutive tissue sections
US9286672B2 (en) * 2012-01-10 2016-03-15 Rutgers, The State University Of New Jersey Integrated multivariate image-based method for disease outcome predicition
JP2013200287A (ja) 2012-03-26 2013-10-03 Kawasaki Gakuen Ｋｉ−６７インデックス算定二重染色法を用いた陽性率測定方法

Also Published As

Publication number Publication date
EP2939026A1 (en) 2015-11-04
JP2016503167A (ja) 2016-02-01
CA2890964A1 (en) 2014-07-03
WO2014102130A1 (en) 2014-07-03
CA2890964C (en) 2023-07-25
AU2013369439A1 (en) 2015-05-28
DK2939026T3 (en) 2017-09-11
ES2639559T3 (es) 2017-10-27
US20150347702A1 (en) 2015-12-03
US20220051804A1 (en) 2022-02-17
US11211167B2 (en) 2021-12-28
EP2939026B1 (en) 2017-07-05
AU2013369439B2 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
JP6405319B2 (ja) 乳癌予知のための画像分析
Potts et al. Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue
Lloyd et al. Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it?
Fitzgibbons et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast
Väyrynen et al. An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer
Knutsvik et al. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays
Focke et al. St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods
Varga et al. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study
Ahn et al. Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens.
Shafi et al. Integrating and validating automated digital imaging analysis of estrogen receptor immunohistochemistry in a fully digital workflow for clinical use
Qi et al. Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients
Kim et al. Risk factors associated with discordant Ki-67 levels between preoperative biopsy and postoperative surgical specimens in breast cancers
Sode et al. Digital image analysis and assisted reading of the HER2 score display reduced concordance: pitfalls in the categorisation of HER2‐low breast cancer
Ács et al. Reproducibility and prognostic potential of Ki-67 proliferation index when comparing digital-image analysis with standard semi-quantitative evaluation in breast cancer
Fulawka et al. Proliferation index evaluation in breast cancer using ImageJ and ImmunoRatio applications
Feng et al. Low Ki67/high ATM protein expression in malignant tumors predicts favorable prognosis in a retrospective study of early stage hormone receptor positive breast cancer
Jonmarker Jaraj et al. Intra-and interobserver reproducibility of interpretation of immunohistochemical stains of prostate cancer
Cho et al. The long-term prognostic performance of Ki-67 in primary operable breast cancer and evaluation of its optimal cutoff value
van Kempen et al. Monitoring Immunohistochemical Staining Variations Using Artificial Intelligence on Standardized Controls
Nassar et al. Trainable immunohistochemical HER2/neu image analysis: a multisite performance study using 260 breast tissue specimens
Wang et al. Laboratory validation studies in Ki-67 digital image analysis of breast carcinoma: a pathway to routine quality assurance
Tobin et al. Automated image analysis of cyclin D1 protein expression in invasive lobular breast carcinoma provides independent prognostic information
Miller et al. Objective analysis of cancer stem cell marker expression using immunohistochemistry
Singh et al. Analytical validation of quantitative immunohistochemical assays of tumor infiltrating lymphocyte biomarkers
Jing et al. Validity and reliability of Ki-67 assessment in oestrogen receptor positive breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180301

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180817

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180914

R150 Certificate of patent or registration of utility model

Ref document number: 6405319

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250